Therapeutic advances in inflammatory bowel disease (IBD) have been universally directed towards patients with established disease to control inflammation, ameliorate symptoms and hinder disease progression, but preventing IBD development or delaying its onset are highly attractive. This Comment discusses the emerging approaches and future promises of interventional disease prevention trials in IBD.
- Sailish Honap
- Nelly Agrinier
- Laurent Peyrin-Biroulet
